The objective was to test the hypothesis that in patients with prostate cancer undergoing radical prostatectomy (RP), diabetic patients are at a higher risk of harboring a high-grade tumor than nondiabetic patients. We examined 2060 consecutive men who underwent RP between 2001 and 2009. Of them, 7.1% had type 2 diabetes mellitus (DM). A high-grade tumor was defined as having a Gleason score X8. Univariable and multivariable logistic regression analyses were used to test the relationship between type 2 DM and high-grade tumor. Mean patient age was 64 years (range: 45-85). Mean total PSA level was 9 ng ml À1 (range: 1-89.5). A significantly higher percentage of diabetic patients had high-grade tumor on biopsy (16.3 vs 7.6%; P ¼ 0.001) and on RP specimen (21.1 vs 11.7%; P ¼ 0.001) in comparison with non-diabetic patients. In multivariable analyses, DM was an independent predictor of high-grade tumor on biopsy (odds ratio ¼ 2.31, P ¼ 0.001) and on final pathological specimen (odds ratio ¼ 2.22, P ¼ 0.002). In patients undergoing RP, those with type 2 DM had a higher risk of harboring a poorly differentiated tumor on final pathological examination.
Introduction
Diabetes mellitus (DM) is a common disease that has reached epidemic proportions. It currently affects B246 million people worldwide (about 5.9% of the adult population). Approximately 85-95% of diabetic individuals in developed countries have type 2 (non-insulin dependent) DM. 1 Prostate cancer (PCa) represents the most common noncutaneous malignant tumor in men. 2 The correlation between DM and PCa has been addressed in several reports, and an inverse association between DM and the risk of PCa has been reported. [3] [4] [5] However, it is still unclear whether this correlation is consistent for all tumor grades. Recently, some authors 6, 7 classified the correlation between DM and PCa according to tumor grade and have reported that DM mainly decreases the risk of low-grade tumors and, to a lesser degree, the risk of high-grade tumors. Consequently, it is plausible to assume that DM changes the proportions of PCa grades favoring high-grade tumors.
Recent analyses of patients undergoing radical prostatectomy (RP) have shown that DM is associated with a higher PCa grade. 8 However, a previous analysis of the CaPSURE database found no association between DM and PCa aggressiveness. 9 It is noteworthy that virtually all the aforementioned studies were based on North American cohorts. [6] [7] [8] [9] Therefore, their results may not be directly applicable to the European population.
In this study, we revisited the relationship between DM and PCa in a cohort of European men who were referred to RP. We tested the hypothesis that the rate of high-grade tumors is higher in diabetic patients than in non-diabetic patients.
Materials and methods

Patient population
Between January 2001 and March 2009, we prospectively collected data from 3091 consecutive patients who underwent RP at our institution. Patients were excluded if age, clinical characteristics and/or pathological characteristics were unknown (717), or if they had undergone neoadjuvant hormonal therapy (301). Finally, only 13 patients reported having type 1 DM. Because this number was small for statistical comparison, these patients were also excluded. These selection criteria yielded 2060 eligible patients. No statistically significant differences were observed between patients who were excluded from the study in comparison with those who were included (data not shown). Informed consent was obtained from all patients, and our institution's institutional review board approved this study. Four dedicated genitourinary pathologists who were blinded to the objective of the study and DM status reviewed all biopsies and RP specimens to determine Gleason score and pathological stage.
Variables definition
All data were abstracted from clinical notes. Age at RP, total PSA at RP, body mass index (BMI) at RP (BMI p25, BMI 425 to p30 and BMI 430 kg m 
Statistical analyses
For the purposes of this study, data analyses were performed retrospectively. Descriptive statistics of categorical variables focused on frequencies and proportions. Means, medians and ranges were reported for continuously coded variables. The w 2 -test, Student's t-test and Mann-Whitney test were used to compare the statistical significance of differences in proportions, means and medians, respectively. Univariable and multivariable logistic regression analyses tested the relationship between DM and highgrade tumor (defined as Gleason score X8). Two sets of logistic regression analyses were performed. First, to examine the relationship between DM and high-grade PCa on biopsy, we adjusted our models for clinical stage, age, PSA, BMI and year category. Second, to examine the relationship between DM and high-grade PCa on the pathological examination of RP specimen, we adjusted our models for pathological stage, age, PSA, BMI and year of surgery. Statistical tests were performed using IBM SPSS 13 for Windows (SPSS, Chicago, IL, USA). All tests were twosided, with a significance level of 0.05. Table 1 shows the clinical and pathological characteristics for all patients (n ¼ 2060). Average patient age was The prevalence of type 2 DM in our cohort was 7.1% (147 of 2060). Diabetic patients were older than nondiabetic patients (mean age: 65.7 vs 64.4 years, respectively; P ¼ 0.03) and were more overweight (BMI 430: 18.4 vs 8.7% kg m À2 , respectively; Po0.001). Fewer diabetic patients than non-diabetic patients (22.4 vs 31.8, respectively; P ¼ 0.001) were operated on in the most recent years of the study (2007) (2008) (2009) ).
Results
There were no statistically significant differences in PSA level (P ¼ 0.7), clinical stage (P ¼ 0.8) or pathological stage (P ¼ 0.4) between diabetic and non-diabetic patients. Interestingly, a significantly higher percentage of diabetic patients had a poorly differentiated PCa (Gleason score X8) in comparison with non-diabetic patients, according to the Gleason score on biopsy (16.3 vs 7.6%, respectively; P ¼ 0.001) and the pathological Gleason score on RP specimen (21.1 vs 11.7%, respectively; P ¼ 0.001).
In univariable analysis, diabetic patients had a 2.3-fold (Po0.001) and 2.4-fold (Po0.001) higher risk of harboring high-grade PCa based on biopsy and pathological examination of RP specimens, respectively. Similarly, after adjustment for confounders in multivariable analysis, diabetic patients had a 2.7-fold (Po0.001) and 2.4-fold (P ¼ 0.001) higher risk of harboring a high-grade tumor on biopsy and pathological examination of the RP specimen, respectively (Tables 2 and 3 ).
Discussion
Several reports have examined the relationship between DM and PCa grade, showing that DM mainly decreases the rate of low-grade tumor and to a lesser degree decreases the rate of high-grade tumor.
6,7 However, a Diabetes mellitus and prostate cancer grade F Abdollah et al considerable number of patients in these studies were not treated with RP. Accordingly, it was not possible to obtain a final pathological grade for these patients. Unfortunately, high-grade PCa may be underestimated on biopsy in up to 38% of cases. [10] [11] [12] [13] Consequently, the reported relationship between DM and tumor grade in the aforementioned studies might not be completely accurate. One recent report examined the relationship between DM and PCa grade in patients who underwent RP. The authors reported that DM was associated with more aggressive disease. 8 Virtually all the aforementioned studies involved North American men. Accordingly, it may be argued that the results of these studies may not be generalizable to other populations. In this study, we reanalyzed the relationship between type 2 DM and high-grade PCa in European patients undergoing RP for organ-confined PCa.
In the current study, the prevalence of type 2 DM was 7.1%. This rate is consistent with population-based report findings.
14 Diabetic patients were not significantly different from non-diabetic patients in terms of PSA or clinical stage. Although it did not reach statistically significant levels, the rate of pathological T3 tumors was higher by 5% in diabetic patients. Interestingly, the rate of high-grade tumor (defined as Gleason score X8) on biopsy in diabetic patients was roughly double of that found in non-diabetic patients. The rate of intermediategrade tumor (defined as Gleason score ¼ 7) was virtually identical in diabetic and non-diabetic patients, whereas the rate of low-grade tumor (defined as Gleason score p6) was significantly lower in diabetic patients. Similarly, on pathological examination of RP specimens, the rate of high-grade tumor was 21.1% in diabetic patients vs only 11.7% in non-diabetic patients. These observations were confirmed in multivariate analyses. Overall, being diabetic increased the risk of high-grade tumor by 2.7-fold (Po0.001) on biopsy and 2.4-fold (P ¼ 0.001) on pathological examination of RP specimens.
These observations corroborate previous reports. For example, Gong et al. 6 reported that the relationship between DM and PCa incidence was different according to the grade of tumor on prostate biopsy. In their study, diabetic patients had a reduction of 47% in the risk of low-grade tumor but a reduction of only 28% in the risk of high-grade tumor. Accordingly, DM may change the proportions of tumor grades mainly by reducing the incidence of low-grade tumors and, to a lesser degree, by reducing the incidence of high-grade tumors. Consequently, in patients with PCa (as in our population sample), the rate of high-grade tumor is higher in diabetic patients than in non-diabetic patients. Similarly, Leitzmann et al. 7 reported that the apparent protection afforded by DM was primarily a result of the inverse relation between DM and low-grade or low-stage PCa.
Recently, Jayachandran et al. 8 reported that in patients referred to RP, diabetic men had a 1.73-fold (P ¼ 0.002) higher risk of high-grade (defined as Gleason score X7) tumor (P ¼ 0.002). Conversely, Chan et al. 9 observed no association between DM and high-grade tumors in multivariable analyses. Similarly, Kasper et al. 15 reported that DM inhibits high-grade tumors more than it inhibits low-grade tumors (odds ratio (OR) ¼ 0.69 vs OR ¼ 0.76, respectively). Interestingly, when they considered only patients in the PSA era, this correlation was inverted, with DM inhibiting low-grade tumors more than highgrade tumors (OR ¼ 0.71 vs OR ¼ 0.77, respectively). The correlation remained consistent for patients in the pre-PSA era (OR ¼ 0.87 vs OR ¼ 0.46, respectively). This discrepancy could be attributed to the fact that many low-grade tumors passed undiagnosed in the pre-PSA era. It is noteworthy that most of the aforementioned studies 6, 7, 15 did not include data about total PSA values and clinical stage in the multivariable analyses that examined the relationship between DM and PCa grade. These variables should be included in the multivariable analysis to minimize intersubjective variances and to decrease the possibility that the observed relationship is the result of a confounder. Moreover, only one of the aforementioned studies 8 used exclusively the definitive pathological Gleason score to classify tumors as either low-or high-grade tumors. Prostate biopsy may misclassify Gleason score in up to 38% of cases. [10] [11] [12] To the best of our knowledge, this report represents the first European study to examine the relationship between DM and PCa grade in patients undergoing RP. In our study, the rate of DM was lower than that found in the North American reports (7.1 vs 10.2-19.0%). 8, 9 This finding corroborates the observed geographical differences in the rate of DM. 1 Nevertheless, DM was an independent predictor of high-grade PCa in patients referred to RP.
Our findings should be considered when counseling diabetic patients. In view of these patients' predisposition to develop a high-grade tumor, regular PSA screening may be advised in order to detect PCa at early stages. However, our findings must be further confirmed in larger prospective studies before being applied in clinical practice. A further understanding of the mechanisms that control the relationship between DM and PCa grade is necessary before we can accurately predict which diabetic patients are at higher risk of harboring high-grade PCa.
Our study is not devoid of limitations. First, because patients who underwent a therapeutic modality other than surgical intervention were not included, our study may not represent the general population. This limitation is shared with a previous report. 8 However, it is not possible to obtain a definitive pathological Gleason grade in patients undergoing therapeutic modalities other than RP. Moreover, our results are in agreement with previously reported population-based studies based on surgically and non-surgically treated patients. 6, 7 However, the magnitude of the relationship between DM and PCa grade is different in our study, which may be related to patient selection.
Second, we were unable to examine the possible influence of differences in PSA screening, the time of onset of DM, the severity of DM and the type of DM on the relationship between DM and PCa. These variables were not available in our database. This limitation is shared by numerous previous studies 6, 8, 9, 16 that examined the relationship between DM and PCa.
Finally, we were unable to evaluate whether DM status was an independent predictor of cancer control outcomes, such as biochemical recurrence-free rate, disease progression and/or survival. Future studies are highly encouraged to examine these end points. Despite its limitation, to date, our study represents the first report that addresses the association between DM and highgrade PCa in European men using exclusively pathological grade information.
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Conclusion
In patients with PCa undergoing radical prostatectomy, those with type 2 DM have a higher risk of harboring high-grade tumor on final pathological examination. This finding should be considered when counseling diabetic patients. A more frequent PSA screening may be useful for these patients in order to detect high-grade tumors in early stages. However, our findings need to be verified in a prospective manner before being applied to clinical practice.
